The predictive value of soluble urokinase-type plasminogen activator receptor in contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100050487

Enrollment

Unknown

Registered

2021-08-28

Start date

2021-09-01

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

contrast induced acute kidney injury

Interventions

Gold Standard:Clinical outcome

Index test:Soluble&#32

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Voluntarily participate in this experiment and sign the informed consent; 2. Aged 18-80 years; 3. Coronary angiography is planned for suspected coronary heart disease; 4. No related contraindications.

Exclusion criteria

Exclusion criteria: 1. Contrast agent allergy; 2. Patients with end-stage renal disease requiring dialysis; 3. History of contrast agent use in the past two weeks; 4. Combined with severe infectious diseases, autoimmune diseases, severe liver insufficiency, malignant tumors, blood system diseases, etc.; 5. Pregnant or lactating patients.

Design outcomes

Primary

Measure	Time frame
soluble urokinase-type plasminogen activator receptor;SEN, SPE, ACC, AUC of ROC, PPV, NPV;	—

Countries

China

Contacts

Public ContactYan Gaoliang

Zhongda Hospital of Southeast University

yanshipingguo@163.com+86 18761890380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026